SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?

• Published in: Frontiers in oncology Vol. 10; p. 1024
• Main Authors: Turcas, Cristina, Moisoiu, Vlad, Stefancu, Andrei, Jurj, Ancuta, Iancu, Stefania D., Teodorescu, Patric, Pasca, Sergiu, Bojan, Anca, Trifa, Adrian, Iluta, Sabina, Zimta, Alina-Andreea, Petrushev, Bobe, Zdrenghea, Mihnea, Bumbea, Horia, Coriu, Daniel, Dima, Delia, Leopold, Nicolae, Tomuleasa, Ciprian
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 29-06-2020
• Subjects: acute promyelocytic leukemia; disease monitoring; DNA methylation; measurable residual disease; Oncology; patient follow-up
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.01024

Acute promyelocytic leukemia (APL) is characterized by a unique chromosome translocation t(15;17)(q24;q21), which leads to the PML/RARA gene fusion formation. However, it is acknowledged that this rearrangement alone is not able to induce the whole leukemic phenotype. In addition, epigenetic processes, such as DNA methylation, may play a crucial role in leukemia pathogenesis. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), involves the covalent transfer of a methyl group (-CH3) to the fifth carbon of the cytosine ring in the CpG dinucleotide and results in the formation of 5-methylcytosine (5-mC). The aberrant gene promoter methylation can be an alternative mechanism of tumor suppressor gene inactivation. Understanding cancer epigenetics and its pivotal role in oncogenesis, can offer us not only attractive targets for epigenetic treatment but can also provide powerful tools in monitoring the disease and estimating the prognosis. Several genes of interest, such as RARA, RARB, p15, p16, have been studied in APL and their methylation status was correlated with potential diagnostic and prognostic significance. In the present manuscript we comprehensively examine the current knowledge regarding DNA methylation in APL pathogenesis. We also discuss the perspectives of using the DNA methylation patterns as reliable biomarkers for measurable residual disease (MRD) monitoring and as a predictor of relapse. This work also highlights the possibility of detecting aberrant methylation profiles of circulating tumor DNA (ctDNA) through liquid biopsies, using the conventional methods, such as methylation-specific polymerase chain reaction (MS-PCR), sequencing methods, but also revolutionary methods, such as surface-enhanced Raman spectroscopy (SERS).